# mAbxience Research S.L.

Source: https://onco.cc/companies/mabxience-research-s-l/  
OnCo record `mabxience-research-s-l` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

mAbxience Research S.L. is a Spain-based biotechnology company running 2 late-stage cancer trials in melanoma and non-small-cell lung cancer.

## Summary

mAbxience Research S.L., based in Madrid, Spain, is a biotechnology company. mAbxience is a vertically integrated biopharmaceutical company that develops biosimilars and operates an independent contract development and manufacturing organisation (CDMO) platform. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in melanoma and non-small-cell lung cancer. The largest, NCT06687369 (A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)), plans to enrol 726 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Tags: ctgov-sponsor
- HQ: Madrid
- Type: biotech
- Website: https://www.mabxience.com

## Sources

- Official website: https://www.mabxience.com
- ClinicalTrials.gov: trials led by mAbxience Research S.L.: https://clinicaltrials.gov/search?lead=mAbxience%20Research%20S.L.

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- trials: [A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L](https://onco.cc/trials/nct06687369/), [Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma](https://onco.cc/trials/nct07221734/)

---
JSON: https://onco.cc/api/v1/entities/mabxience-research-s-l.json